

#### Best Practice in fEVAR in 2016

Barend Mees & Geert Willem Schurink

Maastricht UMC+

The Netherlands



#### Disclosure of Interest


Speaker name: ....Barend Mees.....


- I have the following potential conflicts of interest to report:
- Consulting
- Employment in industry
- Shareholder in a healthcare company
- Owner of a healthcare company
- Other(s)

X I do not have any potential conflict of interest



#### Indications for fEVAR in 2016









# fEVAR versus Open Repair

	Nordon et al. 2009 <sup>39</sup>		Rao et al. 2014 <sup>34</sup>		
	Onen Bennin	fEV/AD	Onen Bennin	fE)/AD	
	Open Repair	fEVAR	Open Repair	fEVAR	
Number of Studies	12	8	21	14	
Number of Patients	1164	368	1575	751	
Perioperative Mortality (%)	3.6	1.4	4.1	4.1	
Major Complications (%)	NS	NS	25	15.7	
Permanent Dialysis (%)	1.4	1.4	2.8	1.9	
Chronic Renal Failure (%)	NS	NS	7.7	19.7	
Secondary Interventions (%)	2.6	15	4.9	12.7	
Target Vessel Patency (fEVAR; 1 year; %)	-	92	-	95	
NS indicates not specified.					



#### fEVAR versus open juxtarenal repair

- Less invasive
- For unfit patients

Lower mortality and morbidity

- Custom-made devices
- More extensive coverage of aorta




### Pararenal AAA

**Infrarenal Aneurysm (short neck)** 


**Juxta/Suprarenal Aneurysm** 









# Workstation / 3D-imaging






# Target vessel distance








# Determine clock position









# Target vessel length








# FEVAR planning (1)




	10	BA	H	p vs	d british	/ 542
Cx (0)	12:45	29	0	82	16 mm	
STIA (M)	12:15	27	9	77	3 40	
ARD (w)	ω:Jo	22	20 7	65	240	Strutts @
ARS (m)	14:15	22	27	7'	14 !!	
Sterl Evan		24	41	=		
انط	2	25:	3-9			
Poul R/ME	2	13	116		$\geq$	Chimme Act
نا لددم	$\geq 1$	15	193			An of 209
mER	5/9	-10	>1	4		
Art li	5/0	0	_/	#		
		(	(	(		
AFC San	PE	VAN +	-1+			
MANA &				Atn	m Wiz	_
				SNA	8×3	8
Goor for	r bur	₹		ALS	Jrz	
True you	ا†ا عمق . کر . د	8/1 2-1-6-1	. 1	ARD	7×1	
gree by	172.d		. (			_,
( 1000						



# FEVAR planning (2)









# Fenestrated grafts

- Zenith Fenestrated (Cook)
- Anaconda Fenestrated (Vascutek)
- Ventura (Endologix)
- Bolton Medical
- Jotec
- Surgeon modified FEVAR
- In situ FEVAR









#### Cook Zenith Fenestrated CE

- Three modules:
  - Fenestrated tube
  - Bifurcated body
  - Iliac leg
- Max. 3 fenestrations





## Cook Zenith Fenestrated CE







#### Cook Zenith Fenestrated Custom Made


More options in design

 Limitations in position and distance between fenestrations

 Long-term durability and experience











## Cook P-Branch




Sobocinski et al. JEVT 2012;19:165-172





# Anaconda Fenestrated





#### Fenestrated Anaconda

- Fenestrations:
  - of any size
  - on any position
- Repositionable
- Flexible for angulated anatomy
- Cannulation from below and/or above






# Fenestrated Anaconda






## Which stent?

#### Uncovered



#### Covered



From: Ricotta et al.. Perspect Vasc Surg Endovasc Ther 2008;20: 174-87




#### Which stent?

#### Covered vs uncovered

Freedom of stenosis @ 24 months:

Uncovered 92%

Covered 97%





# Complex Custom Made (T)EVAR in Maastricht UMC

- fEVAR for pararenal AAA: 84
- f/bEVAR for TAAA: 96
- f/bEVAR for aortic arch aneurysm:





Patients

– Men: 89%

- Age: 61-88 (75) years

– AAA diameter: 47–89 (65) mm

Previous aortic surgery: 35%



Procedure:

```
Last 2 years: 80%
-1F + 1Sc
3F + 1Sc or 4F
```

stented



#### Outcome:

<ul><li>Technical</li></ul>	success	94.6%

<ul><li>30-d mortality</li></ul>	4.1%
----------------------------------	------

Endoleak

•	Type 1 & 3	7	) (	9/	d
	ITYPCIAS	,			/

Renal Insufficiency

•	Mild / 7	Temporary	35%
---	----------	-----------	-----

• Dialysis 3%



Trends since 2014

 One third of our fEVAR cases are fEVAR after EVAR (13 from 34)

 Two thirds of our fEVAR cases with percutaneous access (24 from 34)



#### Limitations of fEVAR

- Planning:
  - Human factor!
- Production time:
  - 6-8 weeks
- Access:
  - Often bilateral 20-22 Fr
- Procedure:
  - Radiation and contrast load


	Mean	SD	Min.	Max.	i-MEET NEXT GENERATION
Procedure characteristics					
DAP (Gy cm <sup>2</sup> )					
All	130	131	15	514	
EVAR	116	122	32	481	
TEVAR	62	46	15	166	CrossMark
FEVAR	217	159	47	514	TE P=0.014
Fluoroscopy time (min:s)					
All	25:26	19:47	1:49	97:47	ric
EVAR	19:46	8:21	7:16	38:31	
TEVAR	9:44	7:20	1:49	26:25	
FEVAR	49:07	21:50	23:27	97:59	P<0.001
Iodinated contrast volume (ml)					
All	92	40	40	200	
EVAR	84	32	50	150	
TEVAR	89	49	40	170	
FEVAR	116	36	65	200	P= NS


C

D




# Fusion Guidance (1)








## fEVAR after fEVAR








# fEVAR for rAAA





# fEVAR for rAAA





#### State of the art fEVAR 2016

 fEVAR has become an established therapy for pararenal AAA

 fEVAR for pararenal AAA has excellent short- and medium term results

Off-the-shelf fEVAR is needed for (sub) acute treatment



#### State of the art fEVAR 2016

- Plan your graft design yourself
- Aim for adequate seal in normal aorta
- Covered stents for target vessels
- Fusion imaging to reduce radiation and contrast load
- Increasing fEVAR after EVAR
- Percutaneous access